10 recruiting. 10 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Recruiting 10 |
| Phase 1 | 1 | Recruiting 1 |
Follow Adrenal Cortex Diseases: new trials by email Literature Review of Adrenal Cortex Diseases trials Research Report on Adrenal Cortex Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer Biospecimen Collection, Cabozantinib, Cemiplimab - Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 48 | 2026-02-22 | 2026-11-06 |
| Cemiplimab as Maintenance Treatment for Advanced Adrenocortical Cancer Cemiplimab - Adrenal Cortical Carcinoma | Phase 2 | Recruiting | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | 31 | 2025-09-18 | 2025-10-06 |
| Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma Camrelizumab, Apatinib, mitotane - Adrenal Cortical Carcinoma, Adrenal Cortical Cancer | Phase 2 | Recruiting | West China Hospital | 28 | 2025-03-15 | 2025-06-03 |
| Phase II Study of PD-1 Antibody Combined With Radiotherapy in Recurrent or Metastatic Adrenal Cortical Carcinoma Triprolizumab, rodiotherapy - Adrenocortical Carcinoma | Phase 2 | Recruiting | Sun Yat-sen University | 18 | 2025-03-14 | 2025-04-29 |
| Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer Pembrolizumab, Biospecimen Collection, Cabozantinib S-malate - Locally Advanced Adrenal Cortex Carcinoma, Adrenal Cortical Carcinoma | Phase 2 | Recruiting | Emory University | 21 | 2025-01-15 | 2026-02-18 |
| Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). Olaparib; 177Lu-DOTATATE - Solid Tumor Cancer, Medulloblastoma | Phase 1 / Phase 2 | Recruiting | Fundación de investigación HM | 25 | 2024-09-20 | 2026-06-04 |
| Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI Dostarlimab, Chemotherapy - Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma | Phase 2 | Recruiting | UNICANCER | 120 | 2024-07-23 | 2025-12-02 |
| Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma Ablative Radiotherapy, Pembrolizumab - Adrenocortical Carcinoma, ACC | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 12 | 2023-09-27 | 2026-04-15 |
| PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP) - Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc) | Phase 2 | Recruiting | National Cancer Institute (NCI) | 70 | 2022-10-24 | 2026-10-16 |
| Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC) Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG, Etoposide, doxorubicin, cisplatin and Mitotane plus Placebo - Adrenocortical Carcinoma | Phase 2 | Recruiting | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | 80 | 2022-06-08 | 2024-08-01 |
Adrenocortical Carcinoma (9) · Adrenal Cortex Neoplasms (3) · Adrenal Gland Neoplasms (3) · Bile Duct Neoplasms (1) · Carcinoma, Neuroendocrine (1) · Cholangiocarcinoma (1) · Cirrhosis, Familial, with Pulmonary Hypertension (1) · Colorectal Neoplasms (1) · Ependymoma (1) · Esthesioneuroblastoma, Olfactory (1) · Glioblastoma (1) · Glioma (1) · Medulloblastoma (1) · Meningioma (1) · Neoplasm Metastasis (1)
Adrenal Gland Diseases (10) · Endocrine Gland Neoplasms (10) · Endocrine System Diseases (10) · Neoplasms by Histologic Type (10) · Neoplasms by Site (10) · Neoplasms, Glandular and Epithelial (10) · Adenocarcinoma (9) · Carcinoma (9) · Neoplasms (9) · Adrenal Cortex Neoplasms (7) · Adrenal Gland Neoplasms (7) · Neoplasms, Connective and Soft Tissue (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Nerve Tissue (2)
Magnetic Resonance Spectroscopy (2) · Mitotane (2) · Specimen Handling (2) · cabozantinib (2) · cemiplimab (2) · pembrolizumab (2) · Cisplatin (1) · Dexamethasone (1) · Doxorubicin (1) · Drug Therapy (1) · Etoposide (1) · Floxuridine (1) · Megestrol Acetate (1) · apatinib (1) · camrelizumab (1)
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (2) · National Cancer Institute (NCI) (2) · Emory University (1) · Fundación de investigación HM (1) · Memorial Sloan Kettering Cancer Center (1) · Sun Yat-sen University (1) · UNICANCER (1) · West China Hospital (1)
United States (4) · China (2) · Italy (2) · France (1) · Spain (1)
Alfredo Berruti (1) · Alfredo Berruti, Prof, MD (1) · Bhavana Konda (1) · Jonathan M Hernandez, M.D. (1) · Marta Osuna Marco, PhD (1) · Nitya Raj, MD (1) · Shahid S. Ahmed, MBBS (1)
PMID 22551107, PMID 27626976, PMID 30367443, PMID 32861807, PMID 33981288, PMID 38989414, PMID 40812353, PMID 42365236
P30CA138292 (1), U10CA180821 (1)